Skip to content
Screener

G&A at other companies

Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$6.05M+12.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$8.1M+54.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$12.82M-13.2%
Vor Biopharma logo
Vor BiopharmaVOR
$17.57M+167%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$7.05M-4.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$13.44M-44.8%

Segments

By segment

See full
Reportable Segment$4.46M+2.4%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$694.34M+1,861%
Enterprise value$633.72M-5,344%
P/S694.3×+683×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
RevenueThree Months Ended June 30, 2026 / $Three Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / $Three Months Ended June 30, 2025 / —Six Months Ended June 30, 2026 / $Six Months Ended June 30, 2026 / —Six Months Ended June 30, 2025 / $Six Months Ended June 30, 2025 / —
Operating expenses:
Research and development11,7008,68022,64618,599
General and administrative4,4554,3529,0538,822
Expense from operations16,15513,03231,69927,421
Loss from operations(16,155)(13,032)(31,699)(27,421)
Other income (expense)
Interest income1,0298041,8321,416
Other expense(26)(230)(52)(155)

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s G&A?
Shattuck Labs, Inc. (STTK) reported G&A of $4.46M in Q2 2026.
How has Shattuck Labs, Inc.'s G&A changed year-over-year?
Shattuck Labs, Inc.'s G&A increased by 2.4% year-over-year, from $4.35M to $4.46M.
What is the long-term trend for Shattuck Labs, Inc.'s G&A?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s G&A has grown at a -2.0% compound annual growth rate (CAGR), from $18.72M to $17.24M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Shattuck Labs, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude